ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
104,549.62
4.54%
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs Yen
156.295
0.60%
Brent Oil
80.005
-0.63%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Immuneering Corporation (IMRX)

  7. Immuneering Corporation (IMRX) ニュース

IMRX

Immuneering (IMRX)

Immuneering Corporation
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:IMRX
日付受信時刻ニュースソース見出しコード企業名
2025/01/1806 : 13Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IMRXImmuneering Corporation
2025/01/1406 : 36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
2025/01/1322 : 00GlobeNewswire Inc.Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
2025/01/0722 : 26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
2025/01/0721 : 00GlobeNewswire Inc.Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional ArmsNASDAQ:IMRXImmuneering Corporation
2025/01/0306 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
2024/12/1922 : 00GlobeNewswire Inc.Immuneering Launches Pancreatic Cancer Advisory BoardNASDAQ:IMRXImmuneering Corporation
2024/12/1722 : 00GlobeNewswire Inc.Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025NASDAQ:IMRXImmuneering Corporation
2024/12/1222 : 00GlobeNewswire Inc.Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced MelanomaNASDAQ:IMRXImmuneering Corporation
2024/11/2722 : 00GlobeNewswire Inc.Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
2024/11/1406 : 05GlobeNewswire Inc.Immuneering Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
2024/11/1406 : 04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
2024/10/1602 : 00AllPennyStocks.comBiotech Shares Rip Following FDA Designation AnnouncementNASDAQ:IMRXImmuneering Corporation
2024/10/1521 : 00GlobeNewswire Inc.Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
2024/10/0305 : 11Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:IMRXImmuneering Corporation
2024/09/1805 : 09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
2024/09/1322 : 40AllPennyStocks.comBiotech Surges Premarket Following Positive Phase 2a ObservationsNASDAQ:IMRXImmuneering Corporation
2024/09/1305 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
2024/09/1305 : 05GlobeNewswire Inc.Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer PatientsNASDAQ:IMRXImmuneering Corporation
2024/08/2921 : 00GlobeNewswire Inc.Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
2024/08/0705 : 12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMRXImmuneering Corporation
2024/08/0705 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
2024/08/0705 : 05GlobeNewswire Inc.Immuneering Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
2024/08/0105 : 05GlobeNewswire Inc.Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
2024/06/1405 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
2024/06/1405 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
2024/05/3005 : 05GlobeNewswire Inc.Immuneering to Present at the Jefferies Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
2024/05/2405 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
2024/05/2405 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
2024/05/2405 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
 Showing the most relevant articles for your search:NASDAQ:IMRX

最近閲覧した銘柄

COIN
XRPUSD
Ripple
FX
USDGBP
US Dollar vs Sterling
COIN
DOGEUSD
Dogecoin
USI
USTECH100
US Tech 100
NYSE
MCD
McDonalds
SPI
SP500
S&P 500
USOTC
ADDYY
Adidas (QX)
COIN
SOLUSD
Solana
COIN
AVAXUSD
Avalanche
NYSE
VZ
Verizon Communications
CCOM
US100
US Tech 100
NASDAQ
AAPL
Apple
NASDAQ
AMZN
Amazon.com
NYSE
AXP
American Express
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有